Evidence map›Paper›PMID 26282567›Full record

ArticleApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine2015

Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors.

Rolf F Barth, Weilian Yang, Robin J Nakkula, Youngjoo Byun, Werner Tjarks, Lai Chu Wu, Peter J Binns, Kent J Riley

Open access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Boron neutron capture therapy: Current status and future perspectives.Cancer communications (London, England) · 2020
    Review
  5. Boron delivery agents for neutron capture therapy of cancer.Cancer communications (London, England) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rolf F BarthThe Ohio State University, Department of Pathology, Columbus, OH 43210, USA. Electronic address: rolf.barth@osumc.edu.
Weilian YangThe Ohio State University, Department of Pathology, Columbus, OH 43210, USA.
Robin J NakkulaThe Ohio State University, Department of Pathology, Columbus, OH 43210, USA.
Youngjoo ByunThe Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, OH 43210, USA.
Werner TjarksThe Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, OH 43210, USA.
Lai Chu WuThe Ohio State University, Department of Molecular and Cellular Biochemistry and Department of Internal Medicine, Columbus, OH 43210, USA.
Peter J BinnsMount Auburn Hospital, Department of Radiology, Cambridge, MA 02138, USA.
Kent J RileyMassachusetts General Hospital, Department of Radiation Oncology, Boston, MA 02114, USA.
The Ohio State University · USMassachusetts General Hospital · USMount Auburn Hospital · US

Funding

Boronated nucleosides for neutron capture therapy of brain tumorsR01CA127935 · NCI · OHIO STATE UNIVERSITY · PI TJARKS, WERNER · 2009 to 2013
$1.3M
NCI NIH HHS 5R01CA127935NCI NIH HHS R01 CA127935
6 · The paper itself

Abstract

In this report we describe studies with N5-2OH, a carboranyl thymidine analog (CTA), which is a substrate for thymidine kinase 1 (TK1), using the F98 rat glioma model. In vivo BNCT studies have demonstrated that intracerebral (i.c.) osmotic pump infusion of N5-2OH yielded survival data equivalent to those obtained with i.v. administration of boronophenylalanine (BPA). The combination of N5-2OH and BPA resulted in a modest increase in MST of F98 glioma bearing rats compared to a statistically significant increase with the RG2 glioma model, as has been previously reported by us (Barth et al., 2008). This had lead us to synthesize a second generation of CTAs that have improved in vitro enzyme kinetics and in vivo tumor uptake (Agarwal et al., 2015).

Indexed as

Boron Neutron Capture TherapyAnimalsBrain NeoplasmsRatsThymidineThymidine KinaseThymidineThymidine Kinasethymidine kinase 1BNCTCarboranyl thymidine analogsF98 rat gliomaN5-2OH

Identifiers

PMID26282567
PMCPMC4685942
OpenAlexW1648223956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.